Volixibat + Placebo

Phase 2Terminated
0 watching 0 views this week Active
49
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Intrahepatic Cholestasis of Pregnancy

Conditions

Intrahepatic Cholestasis of Pregnancy

Trial Timeline

Jan 4, 2021 → Dec 7, 2022

About Volixibat + Placebo

Volixibat + Placebo is a phase 2 stage product being developed by Mirum Pharmaceuticals for Intrahepatic Cholestasis of Pregnancy. The current trial status is terminated. This product is registered under clinical trial identifier NCT04718961. Target conditions include Intrahepatic Cholestasis of Pregnancy.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (3)

NCT IDPhaseStatus
NCT05050136Phase 2Recruiting
NCT04718961Phase 2Terminated
NCT04663308Phase 2Active

Competing Products

20 competing products in Intrahepatic Cholestasis of Pregnancy

See all competitors
ProductCompanyStageHype Score
ApatinibJiangsu Hengrui MedicinePhase 2
52
Apatinib and Adebrelimab in Combination With chemotherapyJiangsu Hengrui MedicinePhase 2
52
ApatinibJiangsu Hengrui MedicinePhase 2
52
FamitinibJiangsu Hengrui MedicinePhase 2
52
Camrelizumab + ApatinibJiangsu Hengrui MedicinePhase 2
52
Durvalumab + SNDX-6352AstraZenecaPhase 2
52
Durvalumab + TremelimumabAstraZenecaPhase 2
52
Pemigatinib + DurvalumabAstraZenecaPhase 2
52
Durvalumab + Gemcitabine + CisplatinAstraZenecaPhase 2
52
PemigatinibIncytePhase 2
49
A4250 (odevixibat)IpsenPhase 3
74
OdevixibatIpsenPre-clinical
20
CGT4859Cogent BiosciencesPhase 1/2
38
LUM001 (Maralixibat)Mirum PharmaceuticalsPhase 2
49
MaralixibatMirum PharmaceuticalsPhase 3
74
MaralixibatMirum PharmaceuticalsPhase 2
49
MaralixibatMirum PharmaceuticalsPhase 2
49
MaralixibatMirum PharmaceuticalsPhase 3
74
Maralixibat + PlaceboMirum PharmaceuticalsPhase 3
74
HMPL-453 + RabeprazoleHUTCHMEDPhase 1
28